Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

This trial is testing the safety and dosing of a new vaccine called FluBHPVE6E7, which is designed to clear a persistent HPV16 infection (one of the strains of the human papillomavirus most likely to cause cervical cancer) in women who have low-grade or no cellular changes in the cervix. **You may be eligible if...** - You are a woman between 18 and 49 years old - You have tested positive for HPV16 on at least two separate tests (at least 3 months apart) - Your cervical cell check shows normal, borderline, or low-grade changes (not high-grade) - You have had a satisfactory colposcopy (internal cervical exam) - Your blood test and ECG results are within normal limits - You are using reliable contraception - You are not pregnant **You may NOT be eligible if...** - You have current high-grade cervical changes (CIN2/3) or have had cervical, vulvar, or vaginal cancer - You have HIV, active hepatitis B or C, or other immune deficiency - You have had any vaccine in the past 6 weeks - You are currently pregnant or breastfeeding - You have had a flu-like illness within the past 3 months - You have an active vaginal or cervical infection - You have a known allergy to oseltamivir (Tamiflu) Talk to your doctor to see if this trial is right for you.